European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis
European Respiratory Journal · 2024-11 · 64 (5) · 2400725
DOI: 10.1183/13993003.00725-2024 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Respiratory Journal, online erschienen am 15.08.2024. Verfasst von Cormac McCarthy und 21 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University College Dublin, Dublin, Ireland cormac.mccarthy@ucd.ie. Hauptthemen laut MEDLINE: Bronchoalveolar Lavage, Granulocyte-Macrophage Colony-Stimulating Factor, Lung Transplantation, Pulmonary Alveolar Proteinosis. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 129 Literaturangaben.
Abstract (Originalsprache)
Background
Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several distinct diseases leading to progressive dyspnoea, hypoxaemia, risk of respiratory failure and early death due to accumulation of proteinaceous material in the lungs. Diagnostic strategies may include computed tomography (CT) of the lungs, bronchoalveolar lavage (BAL), evaluation of antibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF), genetic testing and, eventually, lung biopsy. The management options are focused on removing the proteinaceous material by whole lung lavage (WLL), augmentation therapy with GM-CSF, rituximab, plasmapheresis and lung transplantation. The presented diagnostic and management guidelines aim to provide guidance to physicians managing patients with PAP.
Methods
A European Respiratory Society Task Force composed of clinicians, methodologists and patients with experience in PAP developed recommendations in accordance with the ERS Handbook for Clinical Practice Guidelines and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. This included a systematic review of the literature and application of the GRADE approach to assess the certainty of evidence and strength of recommendations. The Task Force formulated five PICO (Patients, Intervention, Comparison, Outcomes) questions and two narrative questions to develop specific evidence-based recommendations.
Results
The Task Force developed recommendations for the five PICO questions. These included management of PAP with WLL, GM-CSF augmentation therapy, rituximab, plasmapheresis and lung transplantation. Also, the Task Force made recommendations regarding the use of GM-CSF antibody testing, diagnostic BAL and biopsy based on the narrative questions. In addition to the recommendations, the Task Force provided information on the hierarchy of diagnostic interventions and therapy.
Conclusions
The diagnosis of PAP is based on CT and BAL cytology or lung histology, whereas the diagnosis of specific PAP-causing diseases requires GM-CSF antibody testing or genetic analysis. There are several therapies including WLL and augmentation therapy with GM-CSF available to treat PAP, but supporting evidence is still limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, University College Dublin, Dublin, Ireland cormac.mccarthy@ucd.ie.
- Shared first authorship.
- Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.
- School of Medicine, University College Dublin, Dublin, Ireland.
- Service de Pneumologie A, Hôpital Bichat, AP-HP, Université Paris Cité, Inserm UMR-S 1152 PHERE, Paris, France.
- Pneumologia Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
ORCID-Profile: Cormac McCarthy, Francesco Bonella, Clairelyne Dupin, Tiago Alfaro, Markus Fally, Raphael Borie, Ilaria Campo, Vincent Cottin, Aurelie Fabre, Matthias Griese, Alice Hadchouel, Stephane Jouneau, Helmut Prosch, Alexander G Mathioudakis, Elisabeth Bendstrup
Zitieren
APA
McCarthy, C., Bonella, F., O'Callaghan, M., Dupin, C., Alfaro, T., Fally, M., Borie, R., Campo, I., Cottin, V., Fabre, A., Griese, M., Hadchouel, A., Jouneau, S., Kokosi, M., Manali, E., Prosch, H., Trapnell, B. C., Veltkamp, M., Wang, T., …, & Bendstrup, E. (2024). European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. European Respiratory Journal, 64(5), 2400725. https://doi.org/10.1183/13993003.00725-2024
Vancouver
McCarthy C, Bonella F, O'Callaghan M, Dupin C, Alfaro T, Fally M, et al. European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. European Respiratory Journal. 2024;64(5):2400725. doi:10.1183/13993003.00725-2024
BibTeX
@article{McCarthy2024,
author = {McCarthy, Cormac and Bonella, Francesco and O'Callaghan, Marissa and Dupin, Clairelyne and Alfaro, Tiago and Fally, Markus and Borie, Raphael and Campo, Ilaria and Cottin, Vincent and Fabre, Aurelie and Griese, Matthias and Hadchouel, Alice and Jouneau, Stephane and Kokosi, Maria and Manali, Effrosyni and Prosch, Helmut and Trapnell, Bruce C and Veltkamp, Marcel and Wang, Tisha and Toews, Ingrid and Mathioudakis, Alexander G and Bendstrup, Elisabeth},
title = {European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis},
journal = {European Respiratory Journal},
year = {2024},
volume = {64},
number = {5},
pages = {2400725},
doi = {10.1183/13993003.00725-2024}
}
EUVIMED